France’s Sanofi on Monday agreed to buy California-headquartered biotechnology firm Synthorx in a cash deal worth about $2.5 billion as it steps up a push in the lucrative field of cancer drugs under its new chief executive.
France’s Sanofi to buy biotech firm Synthorx for $2.5B
Source: Reuters
Business Events
Health Care Update Webinar
Wednesday, May 25, 2022
Highmark Webinar
Wednesday, June 08, 2022
Security. Technology, Security, Hybrid and Remote Workers
Wednesday, June 29, 2022
Women of Influence
Thursday, June 30, 2022
